Institution
Gdańsk Medical University
Education•Gdańsk, Poland•
About: Gdańsk Medical University is a education organization based out in Gdańsk, Poland. It is known for research contribution in the topics: Population & Cancer. The organization has 4893 authors who have published 11216 publications receiving 260523 citations.
Topics: Population, Cancer, Transplantation, Blood pressure, Breast cancer
Papers published on a yearly basis
Papers
More filters
••
TL;DR: Long-term data from the Global SYMPLICITY Registry representing the largest available cohort of hypertensive patients receiving RDN in a real-world clinical setting demonstrate both the safety and efficacy of the procedure with significant and sustained office and ambulatory BP reductions out to 3 years.
Abstract: AIMS Several studies and registries have demonstrated sustained reductions in blood pressure (BP) after renal denervation (RDN). The long-term safety and efficacy after RDN in real-world patients with uncontrolled hypertension, however, remains unknown. The objective of this study was to assess the long-term safety and efficacy of RDN, including its effects on renal function. METHODS AND RESULTS The Global SYMPLICITY Registry is a prospective, open-label registry conducted at 196 active sites worldwide in hypertensive patients receiving RDN treatment. Among 2237 patients enrolled and treated with the SYMPLICITY Flex catheter, 1742 were eligible for follow-up at 3 years. Baseline office and 24-h ambulatory systolic BP (SBP) were 166 ± 25 and 154 ± 18 mmHg, respectively. SBP reduction after RDN was sustained over 3 years, including decreases in both office (-16.5 ± 28.6 mmHg, P < 0.001) and 24-h ambulatory SBP (-8.0 ± 20.0 mmHg; P < 0.001). Twenty-one percent of patients had a baseline estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m2. Between baseline and 3 years, renal function declined by 7.1 mL/min/1.73 m2 in patients without chronic kidney disease (CKD; eGFR ≥60 mL/min/1.73 m2; baseline eGFR 87 ± 17 mL/min/1.73 m2) and by 3.7 mL/min/1.73 m2 in patients with CKD (eGFR <60 mL/min/1.73 m2; baseline eGFR 47 ± 11 mL/min/1.73 m2). No long-term safety concerns were observed following the RDN procedure. CONCLUSION Long-term data from the Global SYMPLICITY Registry representing the largest available cohort of hypertensive patients receiving RDN in a real-world clinical setting demonstrate both the safety and efficacy of the procedure with significant and sustained office and ambulatory BP reductions out to 3 years.
155 citations
••
Erasmus University Rotterdam1, Victoria Police2, University of the Punjab3, American Board of Legal Medicine4, Wellcome Trust Sanger Institute5, University of Ljubljana6, University of Central Florida7, King's College London8, Innsbruck Medical University9, University of Buenos Aires10, University of Zurich11, University of Turin12, University of Santiago de Compostela13, Rio de Janeiro State University14, National Institute of Standards and Technology15, Pompeu Fabra University16, University of the Western Cape17, Leiden University Medical Center18, University of the Philippines Diliman19, Katholieke Universiteit Leuven20, Wrocław Medical University21, Norwegian Institute of Public Health22, University of Benghazi23, Gdańsk Medical University24, University of Madeira25, Netherlands Forensic Institute26, Linköping University27, University of Tsukuba28, Martin Luther University of Halle-Wittenberg29, National Research Institute of Police Science30, University of Leicester31, Dankook University32, University of Salzburg33, University of Sarajevo34, Aristotle University of Thessaloniki35, Medical University of Warsaw36, Yonsei University37, University of Aveiro38, University of Copenhagen39, Central Forensic Science Laboratory40, Centre for DNA Fingerprinting and Diagnostics41, Kunming Medical University42, Royal Thai Police43, Marche Polytechnic University44, University of Helsinki45, Pennsylvania State University46, University of New Haven47, Josip Juraj Strossmayer University of Osijek48, Eijkman Institute for Molecular Biology49, Charité50, University of Guadalajara51, Mahidol University52, University of North Texas Health Science Center53, University of Cologne54, Comenius University in Bratislava55, University of Costa Rica56, Flinders University57, Charles University in Prague58, DSO National Laboratories59
TL;DR: The value of RM Y‐STRs in identifying and separating unrelated and related males and providing a reference database is demonstrated and the value of Y‐ STRs relative to Yfiler is demonstrated.
Abstract: Relevant for various areas of human genetics, Y-chromosomal short tandem repeats (Y-STRs) are commonly used for testing close paternal relationships among individuals and populations, and for male lineage identification. However, even the widely used 17-loci Yfiler set cannot resolve individuals and populations completely. Here, 52 centers generated quality-controlled data of 13 rapidly mutating (RM) Y-STRs in 14,644 related and unrelated males from 111 worldwide populations. Strikingly, >99% of the 12,272 unrelated males were completely individualized. Haplotype diversity was extremely high (global: 0.9999985, regional: 0.99836–0.9999988). Haplotype sharing between populations was almost absent except for six (0.05%) of the 12,156 haplotypes. Haplotype sharing within populations was generally rare (0.8% nonunique haplotypes), significantly lower in urban (0.9%) than rural (2.1%) and highest in endogamous groups (14.3%). Analysis of molecular variance revealed 99.98% of variation within populations, 0.018% among populations within groups, and 0.002% among groups. Of the 2,372 newly and 156 previously typed male relative pairs, 29% were differentiated including 27% of the 2,378 father–son pairs. Relative to Yfiler, haplotype diversity was increased in 86% of the populations tested and overall male relative differentiation was raised by 23.5%. Our study demonstrates the value of RM Y-STRs in identifying and separating unrelated and related males and provides a reference database.
155 citations
••
TL;DR: The structure, function and clinical significance of adipokines are discussed, which are the link between obesity and obesity-related complications and endocrine function.
155 citations
••
TL;DR: How SNPs affect microRNA-binding sites in these regions, and how mRNA stability changes can lead to disease pathogenesis are examined.
Abstract: In the post-genomic era, the goal of personalized medicine is to determine the correlation between genotype and phenotype. Developing high-throughput genotyping technologies such as genome-wide association studies (GWAS) and the 1000 Genomes Project (http://www.internationalgenome.org/about/#1000G_PROJECT) has dramatically enhanced our ability to map where changes in the genome occur on a population level by identifying millions of single nucleotide polymorphisms (SNPs). Polymorphisms, particularly those within the coding regions of proteins and at splice junctions, have received the most attention, but it is also now clear that polymorphisms in the non-coding regions are important. In these non-coding regions, the enhancer and promoter regions have received the most attention, whereas the 3′-UTR regions have until recently been overlooked. In this review, we examine how SNPs affect microRNA-binding sites in these regions, and how mRNA stability changes can lead to disease pathogenesis.
154 citations
••
TL;DR: The evidence linking obesity with hypertension is examined, the mechanisms underlying this link are reviewed, the potential implications for renal disease are discussed, and the mechanisms behind the association are reviewed.
Abstract: The relevance of both hypertension and obesity, as important public health challenges, is increasing worldwide. Compared with the year 2000, the number of adults with hypertension is predicted to increase by 60% to a total of 1.56 billion by the year 2025 [1]. The growing prevalence of obesity is increasingly recognized as one of the most important risk factors for the development of hypertension. This epidemic of obesity and obesity-related hypertension is paralleled by an alarming increase in the incidence of diabetes mellitus and chronic kidney disease. This editorial examines the evidence linking obesity with hypertension, reviews the mechanisms underlying this link, and discusses its potential implications for renal disease. Earlier studies attributed the link between obesity and hypertension primarily to haemodynamic factors. Recent evidence indicates that the association is much more complex than initially thought.
154 citations
Authors
Showing all 4927 results
Name | H-index | Papers | Citations |
---|---|---|---|
Magdi H. Yacoub | 109 | 1267 | 52431 |
Virend K. Somers | 106 | 615 | 54203 |
Felix Mitelman | 95 | 578 | 35416 |
Andrzej Slominski | 91 | 469 | 27900 |
Nils Mandahl | 86 | 427 | 25006 |
Fredrik Mertens | 84 | 406 | 28705 |
Enriqueta Felip | 83 | 622 | 53364 |
Pieter E. Postmus | 81 | 384 | 24039 |
Wilhelm Kriz | 73 | 222 | 19335 |
Godefridus J. Peters | 73 | 523 | 28315 |
Jacek Jassem | 73 | 602 | 35976 |
Piotr Rutkowski | 72 | 563 | 42218 |
Thomas Frodl | 70 | 258 | 16469 |
Eric J. Velazquez | 70 | 396 | 27539 |
Argye E. Hillis | 68 | 398 | 22230 |